Dual SGLT1 and SGLT2 inhibitor sotagliflozin achieves FDA approval: landmark or landmine?

被引：10

作者：

Packer, Milton ^{[1
,2
]}

机构：

[1] Baylor Heart & Vasc Inst, Dallas, TX 75226 USA

[2] Imperial Coll, London, England

来源：

NATURE CARDIOVASCULAR RESEARCH | 2023年 / 2卷 / 08期

关键词：

D O I：

10.1038/s44161-023-00306-x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The US Food and Drug Administration (FDA) has approved sotagliflozin with a broad heart-failure indication, even in the absence of trial data in patients without diabetes. No one knows what the benefits or risks of inhibiting SGLT1 in the heart might be.

引用

页码：705 / 707

页数：3

共 15 条

[1] Empagliflozin Inhibits Proximal Tubule NHE3 Activity, Preserves GFR, and Restores Euvolemia in Nondiabetic Rats with Induced Heart Failure [J].

Borges-Junior, Avio A. ;

dos Santos, Danubia Silva ;

Benetti, Acaris ;

Polidoro, Juliano Z. ;

Wisnivesky, Aline C. T. ;

Crajoinas, Renato O. ;

Antonio, Ednei L. ;

Jensen, Leonardo ;

Caramelli, Bruno ;

Malnic, Gerhard ;

Tucci, Paulo J. ;

Girardi, Adriana C. C. .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (07) :1616-1629

[2] Na+/H+ exchanger 3 blockade ameliorates type 2 diabetes mellitus via inhibition of sodium-glucose co-transporter 1-mediated glucose absorption in the small intestine [J].

Chan, Leo K. Y. ;

Wang, Yi ;

Ng, Enders K. W. ;

Leung, Po Sing .

DIABETES OBESITY & METABOLISM, 2018, 20 (03) :709-717

[3] Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction [J].

Connelly, Kim A. ;

Zhang, Yanling ;

Desjardins, Jean-Francois ;

Thai, Kerri ;

Gilbert, Richard E. .

CARDIOVASCULAR DIABETOLOGY, 2018, 17

[4] New insight in understanding the contribution of SGLT1 in cardiac glucose uptake: evidence for a truncated form in mice and humans [J].

Ferte, Laura ;

Marino, Alice ;

Battault, Sylvain ;

Bultot, Laurent ;

Van Steenbergen, Anne ;

Bol, Anne ;

Cumps, Julien ;

Ginion, Audrey ;

Koepsell, Hermann ;

Dumoutier, Laure ;

Hue, Louis ;

Horman, Sandrine ;

Bertrand, Luc ;

Beauloye, Christophe .

AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2021, 320 (02) :H838-H853

[5] Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis [J].

Packer, Milton .

CIRCULATION, 2022, 146 (18) :1383-1405

[6] Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study [J].

Posch, Maximilian G. ;

Walther, Niklas ;

Ferrannini, Ele ;

Powell, David R. ;

Banks, Phillip ;

Wason, Suman ;

Dahmen, Raphael .

DIABETES CARE, 2022, 45 (09) :2118-2126

[7] Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice [J].

Ramratnam, Mohun ;

Sharma, Ravi K. ;

D'Auria, Stephen ;

Lee, So Jung ;

Wang, David ;

Huang, Xue Yin N. ;

Ahmad, Ferhaan .

JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2014, 3 (04)

[8] Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure [J].

Sayour, Alex Ali ;

Olah, Attila ;

Ruppert, Mihaly ;

Barta, Balint Andras ;

Horvath, Eszter Maria ;

Benke, Kalman ;

Polos, Miklos ;

Hartyanszky, Istvan ;

Merkely, Bela ;

Radovits, Tamas .

CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)

[9]

SCORED Investigators, 2021, N. Engl. J. Med, V384, P129, DOI [10.1056/NEJMoa2030186, DOI 10.1056/NEJMOA2030186]

[10]

SOLOIST-WHF Trial Investigators, 2021, N. Engl. J. Med, V384, P117, DOI [10.1056/NEJMoa2030183, DOI 10.1056/NEJMOA2030183]

← 1 2 →